Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.60 |
| ▸ | FAP | Q12884 | 1/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 4/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924754 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29565533 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL27902671 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29356868 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6371844 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL29415382 | 0.98 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10658318 | 0.98 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| Bromide SCHEMBL11865608 | 0.98 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10658327 | 0.98 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| Bromide SCHEMBL11865615 | 0.98 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739277-A1 | CONSENSUS PEPTIDES IN HYA | NuPep AS (NO) | 2026-05-13 | — | — | EP | claimed |
| EP-4739330-A1 | CONSENSUS PEPTIDES IN HYA FOR USE IN TREATING DEGENERATED JOINTS | NuPep AS (NO) | 2026-05-13 | — | — | EP | claimed |
| EP-4739331-A1 | CONSENSUS PEPTIDES IN HYA FOR USE IN VISCOSUPPLEMENTATION | NuPep AS (NO) | 2026-05-13 | — | — | EP | claimed |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | JIANGSU DEYUAN PHARMACEUTICAL CO LTD (CN) | 2026-03-26 | — | — | US | claimed |
| CN-121574104-A | Preparation method, condensing agent and application of cosmetic peptide prolyl-lysine | 天津卡普希科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| CN-120148690-A | Preparation method and application of fermented soybean containing bioactive peptide | 澳门科技大学 | 2025-06-13 | — | — | CN | claimed |
| US-12317911-B2 | Flavor compositions and screening methods for identifying the same | MARS, INCORPORATED (US) | 2025-06-03 | — | — | US | claimed |
| WO-2025088200-A2 | ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-05-01 | — | — | WO | claimed |
| CN-114028655-A | Syringe device | 阿达米制药公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | claimed |
| US-11028386-B2 | Morpholino oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2021-06-08 | — | — | US | claimed |
| US-20200040331-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2020-02-06 | — | — | US | claimed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | claimed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | claimed |
| EP-3208277-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2017-08-23 | — | — | EP | claimed |
| US-20170218361-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2017-08-03 | — | — | US | claimed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040331-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | DCLRE1B, RNGTT, RTCB | DPP4 2267/4885DPP8 1192/4885DPP9 1819/4885 |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | VIP, ARGLU1, NGLY1 | DPP4 587/4885DPP8 644/4885DPP9 339/4885 |
| US-11028386-B2 | Morpholino oligonucleotide manufacturing method | DCLRE1B, RNGTT, RTCB | DPP4 2267/4885DPP8 1192/4885DPP9 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.